Results 191 to 200 of about 10,811 (204)

Reply to ANVISA, from FEBRASGO, SBRA and SBRH

JBRA Assisted Reproduction, 2004
openaire   +1 more source

Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022

2023
exaly  

Regulatory Approval for Oncology Products In Brazil: A Comparison Between The Fda And Anvisa Approval Timelines

Value in Health, 2015
M Martin De Bustamante, S Duttagupta, R Beckerman   +2 more
exaly  

Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections

PLoS ONE, 2018
Andrea Renata Cornelio Geyer, Varley Dias Sousa, Damaris Silveira   +2 more
exaly  

ANVISA aprova novo tratamento para câncer de próstata

Revista Feridas, 2022
openaire   +1 more source

The context and quality of evidence used by tobacco interests to oppose ANVISA’s 2012 regulations in Brazil

Global Public Health, 2018
Raphaël Lencucha
exaly  

Implantes hormonais manipulados: novas regras da Anvisa

Femina
Lia Cruz Vaz da Costa Damásio, Maria Celeste Osório Wender   +1 more
openaire   +1 more source

Análise de Impacto Regulatório: uma nova ferramenta para a melhoria da regulação na Anvisa

Revista De Saude Publica, 2011
Alketa Peçi
exaly  

Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

Expert Opinion on Therapeutic Patents, 2014
exaly  

Response to Members' Request Regarding the Germinative Tissue Bank, Forwarded to ANVISA

JBRA Assisted Reproduction, 2006
Maria do Carmo Borges de Souza, Eduardo Pandolfi Passos   +1 more
openaire   +1 more source